ADPT
Adaptive Biotechnologies Corporation
NASDAQ · Healthcare · Biotechnology · US
$24.28
−1.18%Aug 18, 2026, 00:15 UTC
Harlan Robins, co-founder of Adaptive Biotechnologies, raised $15 million for a new startup focused on rethinking how AI trains on scientific data.
Source:Jul 31, 2026, 19:45 UTC
Adaptive Biotechnologies announced the planned separation of its Immune Medicine business to become a pure-play MRD diagnostics company.
Source:Jul 29, 2026, 22:05 UTC
Adaptive Biotechnologies strengthened its balance sheet through a $340 million convertible note offering.
Jul 29, 2026, 20:05 UTC
Adaptive Biotechnologies reported financial results for the second quarter of 2026.
Jul 29, 2026, 00:00 UTC
Harlan Robins departed as Chief Scientific Officer of Adaptive Biotechnologies Corp and became a strategic consultant, effective July 24, 2026.
Jun 16, 2026, 07:55 UTC
Adaptive Biotechnologies Corporation announced its intention to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses.
Jun 15, 2026, 20:05 UTC
Adaptive Biotechnologies announced a proposed offering of $250 million aggregate principal amount of convertible senior notes due 2031 in a private offering to qualified institutional buyers.